Cannabis and Hot Flashes
Cannabis is widely used but lacks clinical trial evidence for menopausal hot flashes.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
About 27% of midlife women report using cannabis for menopause, but no randomized controlled trial has tested whether it actually reduces hot flashes. What exists is self-report: people say it helps them sleep or feel less anxious around hot flashes, which may ease suffering without fixing the symptom itself. Marketing claims about 'menopause strains' or CBD alone are not supported by evidence. Cannabis may be one tool in a personal toolkit—but it's not a treatment in any proven sense.
Not Medical Advice
This article is not medical advice. It summarizes published evidence about cannabis and menopausal hot flashes. Menopause symptoms can overlap with thyroid disease, cardiac issues, and other conditions that require proper clinical evaluation. Talk to a clinician—ideally one familiar with both menopause and cannabis—before using cannabis to manage symptoms, especially if you take other medications, have a history of cardiovascular disease, or are considering hormone therapy.
Plain-Language Summary
Hot flashes (vasomotor symptoms, or VMS) are sudden episodes of heat, sweating, and flushing tied to declining and fluctuating estrogen during perimenopause and menopause. They affect roughly 75% of people going through menopause and can persist for years [1].
Many people use cannabis to cope. A 2020 survey of US military veterans found that about 27% of those experiencing menopause symptoms had used cannabis to manage them, and another 10% were interested in trying [2]. A 2023 Canadian survey reported similar patterns [3].
Use is widespread. Evidence that cannabis actually reduces hot flashes is not. No randomized controlled trial has tested cannabis, THC, or CBD specifically for hot flash frequency or severity. What exists is self-reported symptom relief, plus indirect evidence that cannabis may help related symptoms like sleep and anxiety.
What Probably Works
For hot flashes themselves: nothing in the cannabis category. No cannabinoid product has reached the evidence threshold required to claim efficacy for hot flashes.
For menopausal sleep disturbance (often driven by night sweats), THC-containing products show moderate evidence of shortening time to sleep onset in the short term [4]. Weak / limited However, tolerance develops, and long-term regular use disrupts REM sleep architecture and can produce withdrawal-related insomnia—worsening the symptom people are trying to treat.
For menopausal anxiety or low mood, low-dose THC and CBD have supportive trial data in anxiety disorders broadly [5], though not specifically in menopause populations. Weak / limited Again, this addresses a related symptom, not the hot flash itself.
What Might Work
Reduction in perceived hot flash bother (not frequency). In the 2020 veterans survey, users most commonly reported improvements in sleep and mood, with smaller proportions reporting reduced hot flash discomfort [2]. This is self-report without a control group and does not distinguish hot flash reduction from overall improved coping. Anecdote
CBD for menopausal joint and muscle pain. Observational studies suggest CBD and balanced THC:CBD products may help some chronic pain conditions [6]. Whether this extends to menopause-related musculoskeletal symptoms has not been tested in a controlled trial. Weak / limited
Endocannabinoid system involvement in thermoregulation. Animal studies show CB1 receptor activation affects core body temperature, generally producing cooling at higher doses [7]. Whether this translates to a clinically meaningful reduction in hot flashes in humans remains unknown. Weak / limited
What Doesn't Work or Has Weak Evidence
Marketing claims about 'menopause strains' or CBD-dominant products. Products marketed as menopause-specific blends, suppositories, or tinctures lack clinical trial backing. The popular indica-vs-sativa distinction predicts very little about effects Disputed, and terpene-specific claims (e.g., that linalool or myrcene 'cool' hot flashes) are not supported by controlled human data. No data
Isolated CBD for hot flash frequency. Despite widespread marketing to people in menopause, no published randomized trial shows CBD alone reduces hot flash frequency. No data
Cannabis as a phytoestrogen replacement. Cannabis is not a meaningful source of phytoestrogens, and the cannabinoid system is not an estrogen-signaling pathway. Marketing claims positioning cannabis as a 'natural hormone' are folklore. No data
What We Don't Know
- Whether any cannabinoid, at any dose, reduces objectively measured hot flash frequency (via skin conductance level or ambulatory thermoregulation monitoring).
- Whether effects differ between perimenopause and postmenopause, or by baseline hot flash severity.
- Whether long-term cannabis use during menopause affects bone density, cardiovascular risk, or cognitive outcomes—all of which already fluctuate during this period.
- Interactions with hormone therapy. THC and CBD both inhibit cytochrome P450 enzymes that metabolize estradiol [8], but the clinical significance in hormone therapy users is unclear.
- Optimal route (inhaled, oral, topical), dose, cannabinoid ratio, or duration of use.
If someone offers confident answers to any of these, they are extrapolating from indirect data or personal experience, not evidence.
Comparison with Standard Treatments
Menopausal hormone therapy (MHT/HRT) remains the most effective first-line treatment for moderate-to-severe vasomotor symptoms, reducing hot flash frequency by roughly 75% in randomized trials [1] [9]. Strong evidence For most healthy people under 60 or within 10 years of menopause onset, benefits outweigh risks; this is the evidence-based position of the North American Menopause Society [9].
Non-hormonal pharmaceuticals with controlled trial evidence for hot flashes include:
- SSRIs/SNRIs (paroxetine is FDA-approved for vasomotor symptoms)
- Gabapentin
- Oxybutynin
- Fezolinetant (newer NK3-receptor antagonist)
All have randomized controlled trials showing efficacy [9]. Strong evidence
Cannabis has no comparable evidence base for hot flashes themselves. It should not be positioned as a substitute for treatments that work. It may reasonably be part of a personal toolkit for an informed cannabis user who is already managing hot flashes with an evidence-based treatment—but that is a different claim than 'cannabis treats hot flashes.'
Risks
- Cardiovascular events. Menopause raises baseline cardiovascular risk. Cannabis use, particularly inhaled, is associated with increased risk of acute cardiac events in observational data [10]. This population carries higher baseline risk than younger cannabis users.
- Cognitive effects. Perimenopause already involves cognitive complaints ('brain fog'). THC can worsen short-term memory and concentration in some users, potentially worsening this burden.
- Mood effects. In susceptible users, THC can worsen anxiety—the opposite of the intended effect.
- Sleep rebound. Regular nightly THC use disrupts REM sleep and can produce withdrawal-related insomnia when stopped, paradoxically worsening the sleep problem people are trying to fix.
- Drug interactions. CBD inhibits CYP3A4 and CYP2C19, which metabolize many medications including some used during perimenopause [8]. See Cannabis and Polypharmacy Risks for detail.
- Cannabis use disorder. Cannabis dependence occurs in roughly 9–10% of adult users, higher with daily use [11].
- Product inconsistency. No cannabis product is approved anywhere for menopause. Products are inconsistently labeled, sometimes contaminated, and may not contain what the label claims.
Bottom Line
Cannabis is not a treatment for hot flashes in any evidence-based sense. It may help some of the symptoms that travel with hot flashes—poor sleep, anxiety, or joint pain—but the evidence is weak, and population-specific research in menopause is nearly absent. If hot flashes are disrupting your life, the first conversation with a clinician should be about hormone therapy or evidence-based non-hormonal medications. Cannabis can be part of a personal toolkit for someone who is already an informed user and already managing hot flashes with proven treatments—but call it what it is: a potential coping tool, not a treatment.
Sources
- Peer-reviewed Avis NE, Crawford SL, Greendale G, et al. (2015). Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Internal Medicine, 175(4), 531–539.
- Peer-reviewed Slavin MN, Farmer S, Earleywine M. (2020). Cannabis use to manage menopause symptoms among midlife women veterans. Menopause, 27(11), 1235–1242.
- Peer-reviewed Dahlgren MK, El-Abboud C, Lambros AM, et al. (2022). A survey of medical cannabis use during perimenopause and postmenopause. Menopause, 29(9), 1028–1036.
- Peer-reviewed Babson KA, Sottile J, Morabito D. (2017). Cannabis, cannabinoids, and sleep: a review of the literature. Current Psychiatry Reports, 19(4), 23.
- Peer-reviewed Bergamaschi MM, Queiroz RH, Chagas MH, et al. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology, 36(6), 1219–1226.
- Government National Academies of Sciences, Engineering, and Medicine. (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: National Academies Press.
- Peer-reviewed Fraga D, Zanoni CI, Rae GA, Parada CA, Souza GE. (2009). Endogenous cannabinoids induce fever through the activation of CB1 receptors. British Journal of Pharmacology, 157(8), 1494–1501.
- Peer-reviewed Brown JD, Winterstein AG. (2019). Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. Journal of Clinical Medicine, 8(7), 989.
- Peer-reviewed The North American Menopause Society. (2022). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause, 29(7), 767–794.
- Peer-reviewed Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. (2001). Triggering myocardial infarction by marijuana. Circulation, 103(23), 2805–2809.
- Peer-reviewed Hasin DS, Saha TD, Kerridge BT, et al. (2015). Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry, 72(12), 1235–1242.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Fibromyalgia — Cannabis shows weak evidence for sleep and pain; limited data on long-term use and interac...
- Cannabis and Osteoarthritis — Limited evidence supports cannabis for OA pain and sleep; it does not slow disease progres...
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- THC Dose and Anxiety — Low doses may reduce acute anxiety; higher doses increase it. Evidence is limited, risks a...